Fig. 6: Free kappa/lambda light (lt) chain ratio (turquoise) and immunoglobulin G (orange) levels in patient who achieved disease control while being treated with ABBV-467. | Communications Medicine

Fig. 6: Free kappa/lambda light (lt) chain ratio (turquoise) and immunoglobulin G (orange) levels in patient who achieved disease control while being treated with ABBV-467.

From: Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients

Fig. 6

Patient had relatively slow clinical course after initiation of ABBV-467 for about 8 months despite treatment history of 10 lines after pretreatment including EPD and D-MPV. Disease control over 8 cycles represented by stable immunoglobulin G level combined with a decrease of the patient’s free lt chain ratio until treatment discontinuation due to PD. D-MPV, dexamethasone, methotrexate, procarbazine, vincristine; EPD, elotuzumab, pomalidomide; PD, progressive disease.

Back to article page